Skip to main content


To view more alumni events, click here.

Charles and Mary O’Melia Lecture in Environmental Science
Sep 29 @ 3:00 pm – 4:00 pm

Kimberly Jones, professor and chair of the Department of Civil Engineering at Howard University, will deliver The Charles and Mary O’Melia Lecture in Environmental Science at 3 p.m. on Tuesday, Sept. 29 in Gilman 50.

2015 O'Melia Lecture -- Kimberly Jones of Howard UniversityThe title of Jones’ lecture will be “Can Nanotechnology Solve the Water Crisis? Advances and Obstacles in the Use of Nanomaterials for Water and Wastewater Treatment.”

Jones’ research interests include developing membrane processes for environmental applications, physical-chemical processes for water and wastewater treatment, remediation of emerging contaminants, drinking water quality, and environmental technology.

R. Rhodes Trussell to deliver 2016 Earnest and Agnes Gloyna Distinguished Lecture in Environmental Engineering
Oct 18 @ 3:00 pm – 4:15 pm

R. Rhodes Trussell R. Rhodes Trussell, Chairman and Founder of LA-based Trussell Technologies, Inc., will deliver the 2016 Earnest and Agnes Gloyna Distinguished Lecture in Environmental Engineering from 3 to 4:15 p.m. on Tuesday, Oct. 18. The location of this lecture will be announced closer to the date of the event. A reception will follow. This event is hosted by the Department of Geography and Environmental Engineering.


Canceled – Robert Nerem presents “Regenerative Medicine: The Hype, the Hope, and the Future”
Apr 14 @ 3:30 pm – 4:30 pm
Canceled - Robert Nerem presents "Regenerative Medicine: The Hype, the Hope, and the Future" @ 26 Mudd Hall

This event has been canceled.

Robert M. Nerem (Georgia Institute of Technology) presents “Regenerative Medicine: The Hype, the Hope, and the Future” as part of a special seminar hosted by the Department of Biomedical Engineering, the Institute for NanoBioTechnology, and the Translational Tissue Engineering Center.

Abstract: Although the underlying concepts of tissue engineering and regenerative medicine go back more than 75 years, the term tissue engineering actually was only “coined” in the 1980s. This was followed by the 1990s being the “go-go” years with stem cells emerging as a technology, an industry developing, and the term regenerative medicine beginning to be used. There also was a lot of hype, and following the turn of the century the field entered what might be called the “sobering” years, with private sector activity falling significantly even though the science continued to advance. The last decade, however, has all the marks of being “back to the future.” Advances in cell-based therapies have been fueled by advances in stem cell science and technology and the discovery of what is required to reprogram somatic cells into stem cells, known as induced pluripotent stem (iPS) cells. For cellular therapies, a key question is what is the mechanism of action? For a specific therapy, is the mechanism one of cell replacement or is it a paracrine effect? If the latter, is it possible that one could introduce the appropriate biological signals without the use of cells? In this case the discussion shifts from “my cell is better than your cell” to “my biological signals are better than yours.” Whatever the case, one of the “holy grails” is the neurodegenerative diseases/disorders and the repair/regeneration of the central nervous system. Instead of the mixture of hype and hope in the past, and with an aging population providing the threat of a “tsunami” of neural disorders, regenerative medicine offers the real possibility of cures to these diseases/disorders in the future.

BME and INBT Joint Distinguished Seminar: Arthur J. Coury
Oct 23 @ 4:00 pm – 5:00 pm
BME and INBT Joint Distinguished Seminar: Arthur J. Coury @ Gilman 50

The Johns Hopkins Department of Biomedical Engineering and Institute for NanoBioTechnology co-host a joint distinguished seminar. Arthur J. Coury, University Distinguished Professor in the Department of Chemical Engineering at Northeastern University, will present “Medical Product Translation: Concept to Market and Beyond with Considerations Along the Way.”

Abstract: Developing regulated medical products through all required stages, whether emanating from academic or industrial sources, has led to the understanding of certain principles required to achieve commercial success. Experiences derived from executing product development protocols have generated a list of dozens of variables that should be considered, including technical, economic, regulatory, even ethical topics, before advancing far in this process. Failure to satisfy one or a few of the “imperatives” generated from such an analysis will most likely prevent achieving a successfully marketed product. In this talk, facts and figures of the medical product “playing field” will be presented. Following this, stages of a typical regulated medical product development plan with pitfalls along the way will be offered. Then, a “case study” of a successful vs. unsuccessful commercialized medical device will be provided and explained in light of the “imperatives.” Finally, a note on the potential value of an academic license to a medical product company will be suggested.

Back to top